Your browser doesn't support javascript.
loading
Additive effects of brimonidine tartrate 0.1%/brinzolamide 1% fixed-dose combination in prostaglandin analog-treated Japanese glaucoma patients.
Sakata, Rei; Mizoue, Shiro; Yoshikawa, Keiji; Adachi, Misato; Ohkubo, Shinji; Hamada, Naoki; Naito, Tomoko; Muramatsu, Tomoyuki; Hara, Takeshi; Asato, Ryo; Aihara, Makoto.
Afiliación
  • Sakata R; Department of Ophthalmology, Graduate School of Medicine and Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
  • Mizoue S; Yotsuya Shirato Eye Clinic, Yotsuya, Tokyo, Japan.
  • Yoshikawa K; Department of Ophthalmology, Ehime University Graduate School of Medicine, Toon, Ehime, Japan.
  • Adachi M; Department of Ophthalmology, Minami-Matsuyama Hospital, Matsuyama, Ehime, Japan.
  • Ohkubo S; Yoshikawa Eye Clinic, Machida, Tokyo, Japan.
  • Hamada N; Eye Rose Clinic, Chiyoda, Tokyo, Japan.
  • Naito T; Ohkubo Eye Clinic, Kanazawa, Ishikawa, Japan.
  • Muramatsu T; Omiya Hamada Eye Clinic, Saitama, Saitama, Japan.
  • Hara T; Grace Eye Clinic, Okayama, Okayama, Japan.
  • Asato R; Muramatsu Eye Clinic, Susono, Shizuoka, Japan.
  • Aihara M; Hara Eye Hospital, Utsunomiya, Tochigi, Japan.
Jpn J Ophthalmol ; 67(6): 668-677, 2023 Nov.
Article en En | MEDLINE | ID: mdl-37596444
PURPOSE: A brimonidine tartrate 0.1%/brinzolamide 1% fixed-dose combination (BBFC) was recently approved for glaucoma and ocular hypertension treatment in Japan. We investigated the efficacy and safety of BBFC used concomitantly with prostaglandin analogs (PG) or a PG/beta-blocker fixed-dose combination (PG/beta FC). STUDY DESIGN: This was a prospective, open-label, multicenter study. PATIENTS AND METHODS: We enrolled Japanese patients with open-angle glaucoma. BBFC (Ailamide) was concomitantly administered to either the PG or the PG/beta FC group, and intraocular pressure (IOP) and safety were evaluated at 4 and 12 weeks. The groups were stratified into low and high IOP baseline groups based on the median baseline IOP. RESULTS: We enrolled 100 patients, 91 of whom completed the 12-week follow-up. The mean ages were 67.1 and 65.7 years in the PG group (n = 45, baseline IOP of 15.7 ± 2.3 mmHg) and the PG/beta FC group (n = 46, baseline IOP of 16.3 ± 2.3 mmHg), respectively. After BBFC administration, IOPs at 4 and 12 weeks were 13.0 ± 2.0 and 13.0 ± 2.6 mmHg (P < 0.0001) in the PG group, respectively, and 13.7 ± 2.4 and 13.7 ± 2.2 mmHg (P < 0.0001) in the PG/beta FC group, respectively. IOP decreased by - 2.0 ± 1.8 mmHg (P < 0.0001) and -1.9 ± 1.4 mmHg (P < 0.0001) in the low baseline PG group (14.1 mmHg) and low baseline PG/beta FC group (14.8 mmHg) at 12 weeks, respectively. Sixteen adverse events were identified, all of which were common and did not affect visual acuity. CONCLUSIONS: BBFC can be used concomitantly with PG or PG/beta FC to reduce IOP without serious complications.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Glaucoma de Ángulo Abierto / Hipertensión Ocular Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Jpn J Ophthalmol Año: 2023 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Japón
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Glaucoma de Ángulo Abierto / Hipertensión Ocular Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Jpn J Ophthalmol Año: 2023 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Japón